摘要
面对全球约1.7亿慢性丙肝患者,现今的标准治疗方案,即聚乙二醇干扰素(Peg-IFN)联合利巴韦林(RBV),其总治愈率不足50%。因此,近年来旨在提高治愈率的直接抗病毒药物(DAAs)不断问世,其中,丙型肝炎病毒(HCV)聚合酶抑制剂索福布韦作用于病毒RNA复制的NS5B聚合酶位点,中止HCV复制。相较于标准治疗方案,基于索福布韦的联合治疗方案治愈率更高。本文就索福布韦的药理作用、药动学、临床研究及安全性等作一综述。
Approximately 170 million people worldwide are chronically infected with the hepatitis C virus （HCV）, the available therapeutic options for these patients is the combination of pegylated interferon （Peg-IFN） plus ribavirin that overall resulted in HCV eradication in less than a half of the patients. In recent years, several direct-acting antiviral agents （DAAs） have been developed. As a new HCV polymerase inhibitor, sofosbuvir binds to the NS5B active site, causing termination of HCV RNA chain replication. In comparison with conventional Peg- IFN/RBV treatment, sofosbuvir-based therapy has greater response rates. In this paper, we reviewed the pharmacology, pharmacokinetics, clinical study and safety of sofosbuvir.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2014年第4期373-376,390,共5页
Chinese Journal of New Drugs
